Akari Therapeutics PLC (AKTX)
1.29
-0.07
(-5.15%)
USD |
NASDAQ |
May 06, 15:49
Akari Therapeutics EPS Diluted (Quarterly)
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2022 | -1.914 |
| March 31, 2022 | -1.932 |
| December 31, 2021 | -2.490 |
| September 30, 2021 | -0.6248 |
| June 30, 2021 | -2.259 |
| March 31, 2021 | -3.035 |
| December 31, 2020 | -13.84 |
| September 30, 2020 | 0.5395 |
| June 30, 2020 | -4.956 |
| March 31, 2020 | -2.977 |
| December 31, 2019 | -7.304 |
| September 30, 2019 | -2.603 |
| June 30, 2019 | -5.124 |
| March 31, 2019 | -3.220 |
| December 31, 2018 | -4.445 |
| September 30, 2018 | -4.701 |
| June 30, 2018 | -20.00 |
| Date | Value |
|---|---|
| March 31, 2018 | -1.755 |
| December 31, 2017 | -20.00 |
| September 30, 2017 | -20.00 |
| June 30, 2017 | -0.5435 |
| March 31, 2017 | -20.00 |
| December 31, 2016 | -20.00 |
| September 30, 2016 | -0.7101 |
| June 30, 2016 | -20.00 |
| March 31, 2016 | -5.070 |
| December 31, 2015 | 40.00 |
| September 30, 2015 | -120.00 |
| June 30, 2015 | -4.00 |
| March 31, 2015 | -4.00 |
| December 31, 2014 | -20.00 |
| September 30, 2014 | -6.082 |
| June 30, 2014 | -80.00 |
| March 31, 2014 | -80.00 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-13.84
Minimum
Dec 2020
0.5395
Maximum
Sep 2020
-3.732
Average
-2.603
Median
Sep 2019
EPS Diluted (Quarterly) Benchmarks
| DBV Technologies SA | -0.055 |
| Cellectis SA | -0.70 |
| Adaptimmune Therapeutics PLC | -0.18 |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | -4.657 |
EPS Diluted (Quarterly) Related Metrics
| Enterprise Value | 6.931M |
| Earnings Yield | -158.5% |